• NeuroOne Medical Technologies posted fiscal Q2 net loss of $2.1 million, or $0.25 per share, narrowing from a year earlier.
• Product revenue rose 72% year over year to $2.4 million, while product gross profit was $1.3 million and gross margin was 53.8%.
• Operating expenses eased to $3.4 million, with R&D expense at $1.5 million and SG&A expense at $1.9 million.
• Cash and cash equivalents fell to $2.8 million as of March 31, 2026, with working capital at $5.7 million and no debt outstanding.
• Completed 16 OneRF Trigeminal Neuralgia procedures with all patients reportedly pain free; targeted commercial availability of drug delivery system in second half of fiscal 2026 for investigational clinical or animal studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-054744), on May 12, 2026, and is solely responsible for the information contained therein.